Table 4.
Health system perspective results of Prophylactic Emicizumab (without discount) vs bypassing agents for severe haemophilia A patients with inhibitors in India.
| Treatment | Cost of treatment | Incremental cost | QALYs gained | Incremental utility | ICUR |
|---|---|---|---|---|---|
| Prophylactic Emicizumab | 537,892 USD (39,769,582.9 INR) | – | 7.18 | – | – |
| On-demand Recombinant Factor VIIa | 920394.6 USD (68,050,295.1 INR) | – | 6.45 | – | – |
| On-demand FEIBA | 427718.9 (31,623,824.6 INR) | – | 6.55 | – | – |
| Prophylactic Emicizumab vs Recombinant factor VIIa | – | −382502.7 USD (−28,280,719.6 INR) | – | 0.732 | −522236 USD (38,612,040.9 INR) |
| Prophylactic Emicizumab vs FEIBA | – | 110,173.1 USD (8,145,758.3 INR) | – | 0.626 | 175,995 USD (13,012,366.3 INR) |
APCC - Factor eight inhibitor bypass activity (activated prothrombin complex concentrates); ICU-Intensive Care Unit; INR – Indian Rupees; SAE – Serious Adverse Events; USD – United States Dollars; QALY-Quality adjusted life years.